Abstract

BackgroundThe response to treatment for juvenile idiopathic arthritis (JIA) can be staged using clinical features. However, objective laboratory biomarkers of remission are still lacking. In this study, we used machine learning to predict JIA activity from transcriptomes from peripheral blood mononuclear cells (PBMCs). We included samples from children with Native American ancestry to determine whether the model maintained validity in an ethnically heterogeneous population.MethodsOur dataset consisted of 50 samples, 23 from children in remission and 27 from children with an active disease on therapy. Nine of these samples were from children with mixed European/Native American ancestry. We used 4 different machine learning methods to create predictive models in 2 populations: the whole dataset and then the samples from children with exclusively European ancestry.ResultsIn both populations, models were able to predict JIA status well, with training accuracies > 74% and testing accuracies > 78%. Performance was better in the whole dataset model. We note a high degree of overlap between genes identified in both populations. Using ingenuity pathway analysis, genes from the whole dataset associated with cell-to-cell signaling and interactions, cell morphology, organismal injury and abnormalities, and protein synthesis.ConclusionsThis study demonstrates it is feasible to use machine learning in conjunction with RNA sequencing of PBMCs to predict JIA stage. Thus, developing objective biomarkers from easy to obtain clinical samples remains an achievable goal.

Highlights

  • The response to treatment for juvenile idiopathic arthritis (JIA) can be staged using clinical features

  • One of the underappreciated advances in the field of pediatric rheumatology has been the recognition that therapeutic response during the course of treated juvenile idiopathic arthritis (JIA) can be staged based on specific clinical features [1]

  • Poppenberg et al Arthritis Research & Therapy (2019) 21:230 hampered by the considerable inter-patient variation that is observed in gene expression studies of children with JIA, problems that are compounded when complex cell types such as peripheral blood mononuclear cells (PBMCs) are used [6]

Read more

Summary

Introduction

The response to treatment for juvenile idiopathic arthritis (JIA) can be staged using clinical features. One of the underappreciated advances in the field of pediatric rheumatology has been the recognition that therapeutic response during the course of treated juvenile idiopathic arthritis (JIA) can be staged based on specific clinical features [1]. Using hybridization-based gene microarrays, our Poppenberg et al Arthritis Research & Therapy (2019) 21:230 hampered by the considerable inter-patient variation that is observed in gene expression studies of children with JIA, problems that are compounded when complex cell types such as peripheral blood mononuclear cells (PBMCs) are used [6]. Augmented computational power and new methods have facilitated successful classification even using heterogeneous populations, such as PBMCs. For instance, Showe et al used a support vector machine model of 29 genes expressed in PBMCs to distinguish between nonsmall cell lung cancer and non-malignant lung disease with 86% accuracy [7]. Machine learning has been successful in a wide spectrum of disease classification problems

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call